Bend Bioscience Adds Commerical Spray Drying & Granulation in Georgia

2 April 2025 -- Florida, US -- Bend Bioscience, a leading innovation, science, and pharmaceutical services partner, today announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its 120,000-square-foot facility in Gainesville, Georgia. The addition of this equipment will expand the Gainesville facility’s capabilities to provide technologically advanced absorption- and bioavailability-enhanced products, and comprehensive clinical and commercial scale oral dose forms.

Featuring a state-of-the-art GEA PSD-4, the new spray drying suite will include adjacent secondary vacuum drying systems, multiple tank sizes to accommodate flexible campaigns and batch sizes, a dual-stage condenser capable of handling a wide range of process solvents, and the ability to process highly potent APIs. The new equipment is being shipped to the Gainesville facility this month and the installation process will begin immediately to align with potential customer timelines.

"Our FDA-inspected Gainesville site is known for its exceptional customer service, and these latest additions demonstrate our commitment to providing strong, innovative, and comprehensive solutions that empower our customers to bring their transformative therapies to market,” said Owen Murray, CEO of Bend Bioscience. “This expansion not only reinforces our position as a leader in the pharmaceutical services industry, but also allows us to meet the demands of significant near-term growth through our network of capabilities and expertise in enhancing pharmacokinetics, particle engineering and modified release forms.”

These new capabilities complement the company’s clinical development expertise in spray dried dispersions at its site in Bend, Oregon, and strengthen Bend Bioscience’s ability to support both existing and new early-phase customers seeking bioavailability solutions and oral dose forms from early-phase development to reliable commercial supply of marketed products.

The Gainesville facility specializes in oral solid dosage forms, and is a center of excellence for commercial manufacturing, modified release and multiparticulates. It is equipped to handle DEA schedule (I-V) and potent compounds, and has its own analytical, late-phase tech transfer teams, and provides specialist packaging capabilities.

About Bend Bioscience
Formed from three specialist CDMOs, the new Bend Bioscience offers bigger solutions and bolder science across small molecule capabilities and enabling technologies. From pre-clinical to commercial scale, Bend provides its clients with the highest levels of service and science, combining the broad capabilities of a large CDMO with the flexibility and speed of an expert partner. We employ our scientific expertise to optimize your formulation designs with a focus on enhanced pharmacokinetics, and deploying enabling technologies such as spray dried dispersions, particle engineering, multi-particulate dosage forms and modified release technologies to affect desired release profiles and in vivo bioavailability. Our partnering approach brings molecules through the clinic, to scaled manufacturing and launch through our network of three specialized, newly expanded facilities in the U.S., from where we offer accelerated solutions for orphan, breakthrough and specialty programs, as well as tech transfer expertise to ease transition from early development to commercial production. To find out more, visit bendbioscience.com.